Skip to main content
Quest Diagnostics Home
Haystack MRD™ logo
Contact us
Call
Menu

A hypersensitive, tumor-informed test option

Haystack MRD enhances your expertise, uncovering residual disease in cancer patients so you can evaluate their response to surgery and intervene when you need to.

Based on more than 20 years of research developed by cancer genomics pioneers, Haystack MRD’s purpose-built, high-precision science delivers novel insights that lead to optimal treatment decision-making.

New levels of clarity for your treatment decisions

Sensitivity matters when looking for the lowest levels of disease, such as residual disease after surgery or response to adjuvant chemotherapy. Haystack MRD minimizes false negatives by detecting ultralow levels of ctDNA, providing confidence in therapeutic decisions.1


Real-world impact

Through our early experience program, clinicians explored the power of Haystack MRD across multiple common and rare solid tumor types, and >90% reported in a survey that Haystack MRD impacted their treatment decisions.2

Learn firsthand the capabilities of an ultrasensitive ctDNA detection test to help guide your patients confidently through their treatment journey.

How can definitive data on disease detection ease your patient's mind?

 

When you’re more informed about your patient’s true disease status, they’re more informed too. And when that information allows you to be proactive or helps avoid unnecessary treatment, you can help improve your patient's confidence in your care, and ultimately, their outcomes.

smiling man with DNA strand graphic accent

Get support across the cancer care continuum

Haystack MRD seamlessly integrates into the Quest Diagnostics comprehensive oncology testing portfolio. So now you can experience end-to-end reliability powered by Quest-credentialed staff, labs, logistics, service, reporting, test menu, and technology.

Uncover the data you need to make timely, confident decisions for cancer treatment

The DYNAMIC study demonstrated that applying a ctDNA-guided approach could significantly reduce the use of adjuvant chemotherapy without compromising recurrence or survival at 5 years.

See the data

Quest is ready to support you and your lab with implementing Haystack MRD into your workflow

Do you have questions about Haystack MRD? Are you interested in learning more about how you can use this ultrasensitive testing to empower your care? Quest is here to help! Connect with a Haystack MRD representative today.

Get in touch

References

  1. Data on file. Haystack Oncology; 2024.
  2. Data on file. Quest Diagnostics; 2024. Survey responses from Haystack MRD Early Experience users as of 11/2024.

Our company

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.